Source-grounded facts extracted from Vistagen Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Joanne Curley departed as Director at Vistagen Therapeutics, Inc..
“On June 16, 2026, Ms. Margaret FitzPatrick, and on June 17, 2026, Dr. Joanne Curley, each a member of the Board of Directors of Vistagen Therapeutics, Inc. (the “ Company ”), notified the Company of her decision not to stand for re-election at the Company’s 2026 Annual Meeting of Stockholders.”
Margaret FitzPatrick departed as Director at Vistagen Therapeutics, Inc..
“On June 16, 2026, Ms. Margaret FitzPatrick, and on June 17, 2026, Dr. Joanne Curley, each a member of the Board of Directors of Vistagen Therapeutics, Inc. (the “ Company ”), notified the Company of her decision not to stand for re-election at the Company’s 2026 Annual Meeting of Stockholders.”
Vistagen Therapeutics, Inc. reported fiscal year ended March 31, 2026 results: net income $69.7 million.
“Net loss was $69.7 million for the fiscal year ended March 31, 2026, compared with $51.4 million for the fiscal year ended March 31, 2025.”
Angel S. Angelov, M.D., MBA was appointed as Chief Medical Officer at Vistagen Therapeutics, Inc..
“On May 18, 2026 (the “ Effective Date ”), Vistagen Therapeutics, Inc. (the “ Company ”) appointed Angel S. Angelov, M.D., MBA to serve as the Company’s Chief Medical Officer.”
Vistagen Therapeutics, Inc. received a nasdaq noncompliance notice notice regarding audit committee (rules 5605(c)(2)).
“April 1, 2026, Vistagen Therapeutics, Inc. (the “ Company ”) notified The Nasdaq Stock Market LLC (“ Nasdaq ”) of its current non-compliance with Nasdaq Listing Rule 5605(c)(2), which requires the Audit Committee of a Nasdaq-listed company to have at least three members from its Board of Directors, each meeting independence and certain other criteria. As disclosed in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 18, 2026, Ms. Mary Rotunno resigned from the Company’s Board of Directors (the “ Board ”), effective April 1, 2026 (the “ Resignat”
Vistagen Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“February 3, 2026, Vistagen Therapeutics, Inc. (the “ Company ”) received a letter (the “ Notice ”) from the Listing Qualifications Staff of The Nasdaq Stock Market, LLC (“ Nasdaq ”) indicating that, based upon the closing bid price of the Company’s common stock, par value $0.001 per share (“ Common Stock ”), for the last 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2). The Letter has no immediate effe”
Vistagen Therapeutics, Inc. reported fiscal year 2024 third quarter ended December 31, 2023 results: net income $6.3 million.
“Net loss: Net loss was $6.3 million and $9.8 million for the three months ended December 31, 2023, and 2022, respectively.”
Vistagen Therapeutics, Inc. reported financial results for fiscal year 2024 second quarter ended September 30, 2023.
“On November 9, 2023, Vistagen Therapeutics, Inc. (the “ Company ”) issued a press release to announce the Company’s financial results for its fiscal year 2024 second quarter ended September 30, 2023.”
Joshua Prince was appointed as Chief Operating Officer at Vistagen Therapeutics, Inc..
“On October 24, 2023, Joshua Prince was appointed to serve as the Chief Operating Officer of Vistagen Therapeutics, Inc. (the “ Company ”).”
Vistagen Therapeutics, Inc. entered into Underwriting Agreement with Jefferies LLC, Stifel, Nicolaus & Company, Incorporated, and William Blair & Company, L.L.C. valued at combined offering price for each share of Common Stock, accompanying T1 Warrant and accompanying T2 (effective 2023-10-02).
“On October 2, 2023, Vistagen Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Stifel, Nicolaus & Company, Incorporated, and William Blair & Company, L.L.C., as the representatives of the underwriters listed on Schedule A attached thereto (the “Underwriters”), in connection with the underwritten offering, issuance and sale by the Company of 15,010,810 shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”), pre-funded warrants to purchase up to 3,577,240 shares of Common Stock (the “Pre-Funded Warrants”), warrants to purchase up to 9,294,022 shares of Common Stock (or pre-funded warrants to purchase up to 9,294,022 shares of Common Stock in lieu thereof) (the “T1 Warrants”) and warrants to purchase 11,265,086 shares of Common Stock (or pre-funded warrants to purchase up to 11,265,086 shares of Common Stock in lieu thereof) (the “T2 Warrants”).”
Vistagen Therapeutics, Inc. shareholders approved Ratification of Appointment of Auditors at the 2023-09-25 meeting.
“Proposal No. 4 – Ratification of Appointment of Auditors For Against Abstain Votes 3,933,402 334,951 42,733”
Vistagen Therapeutics, Inc. shareholders approved Amendment to the Vistagen Therapeutics, Inc. Amended and Restated 2019 Omnibus Equity Incentive Plan at the 2023-09-25 meeting.
“Proposal No. 3 – Amendment to the Vistagen Therapeutics, Inc. Amended and Restated 2019 Omnibus Equity Incentive Plan For Against Abstain Votes 1,389,517 667,326 28,756”
Vistagen Therapeutics, Inc. shareholders approved Advisory Vote to Approve Executive Compensation (Say-on-Pay Proposal) at the 2023-09-25 meeting.
“Proposal No. 2 – Advisory Vote to Approve Executive Compensation (Say-on-Pay Proposal) For Against Abstain Votes 1,382,535 607,263 95,801”
Vistagen Therapeutics, Inc. shareholders approved Election of Directors at the 2023-09-25 meeting.
“Proposal No. 1 – Election of Directors For Withheld Ann M. Cunningham, MBA 1,443,789 641,810”
Vistagen Therapeutics, Inc. entered into Exclusive Negotiation Agreement with Fuji Pharma Co., Ltd. valued at $1,500,000 (effective 2023-09-01).
“On September 1, 2023, Vistagen Therapeutics, Inc. (the “ Company ”) entered into an Exclusive Negotiation Agreement (the “ Negotiation Agreement ”) by and among the Company and Fuji Pharma Co., Ltd.”
Cynthia Anderson was appointed as Chief Financial Officer at Vistagen Therapeutics, Inc..
“announced the appointment of Ms. Cynthia Anderson, C.P.A., as the Company’s Chief Financial Officer”
Jerrold Dotson retired as Chief Financial Officer at Vistagen Therapeutics, Inc..
“Ms. Anderson replaces Mr. Jerrold Dotson upon his retirement, effective August 21, 2023”
Vistagen Therapeutics, Inc. reported financial results for fiscal year 2024 first quarter ended June 30, 2023.
“On August 10, 2023, Vistagen Therapeutics, Inc. (the “ Company ”) issued a press release to announce the Company’s financial results for its fiscal year 2024 first quarter ended June 30, 2023.”
Jerrold D. Dotson departed as Vice President and Chief Financial Officer at Vistagen Therapeutics, Inc..
“On July 7, 2023, Vistagen Therapeutics, Inc. (the “ Company ”) announced that Jerrold D. Dotson, CPA, Vice President and Chief Financial Officer (principal financial and accounting officer), intends to retire from the Company on or about August 31, 2023.”
Vistagen Therapeutics, Inc. reported financial results for fiscal year ended March 31, 2023.
“today provided a corporate update and reported financial results for its fiscal year 2023 ended March 31, 2023”
Vistagen Therapeutics, Inc. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).
“September 5, 2023 (the “ Extension Period ”), to regain compliance with the requirement for the Company’s common stock, par value $0.001 per share (“ Common Stock ”), to maintain a minimum bid price of $1.00 per share for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “ Minimum Bid Price Requirement ”). The Extension Notice has no immediate effect on the continued listing status of the Company's Common Stock on the Nasdaq Capital Market. The Company's listing on the Nasdaq Capital Market remains fully effective. As previously disclosed in th”
Vistagen Therapeutics, Inc. reported financial results for fiscal year 2023 third quarter ended December 31, 2022.
“On February 7, 2023, Vistagen Therapeutics, Inc. (the “ Company ”) issued a press release to announce the Company’s financial results for its fiscal year 2023 third quarter ended December 31, 2022.”
Vistagen Therapeutics, Inc. entered into Agreement and Plan of Merger with Pherin Pharmaceuticals, Inc. and Kevin McCarthy as Stockholder Representative (effective 2022-12-20).
“On December 20, 2022, Vistagen Therapeutics, Inc. (the “ Company ”) entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) by and among the Company, VTGN Merger Sub, Inc., a wholly-owned subsidiary of the Company (“ Merger Sub ”), Pherin Pharmaceuticals, Inc. (“ Pherin ”), and Kevin McCarthy in the capacity of Stockholder Representative.”
Vistagen Therapeutics, Inc. reported financial results for its fiscal year 2023 second quarter ended September 30, 2022.
“On November 10, 2022, Vistagen Therapeutics, Inc. (the “ Company ”) issued a press release to announce the Company’s financial results for its fiscal year 2023 second quarter ended September 30, 2022.”
Vistagen Therapeutics, Inc. shareholders rejected Approval of an Amendment to the Company's Bylaws at the 2022-10-28 meeting.
“Proposal No. 6 – Approval of an Amendment to the Company ’ s Bylaws For Against Abstain Votes 65,592,186 24,302,176 3,454,611 The vote required to approve Proposal No. 6 to amend the Company’s Second Amended and Restated Bylaws, as amended, to allow the Board in its sole discretion to determine, from time to time, the number of directors constituting the Board was the affirmative vote of a majority of the 206,836,945 outstanding shares of the Company’s Common Stock entitled to vote as of the record date for the Annual Meeting. Accordingly, stockholders did not approve Proposal No. 6.”
Vistagen Therapeutics, Inc. shareholders approved Approval of Discretionary Authorization to Implement a Reverse Stock Split at the 2022-10-28 meeting.
“Proposal No. 5 – Approval of Discretionary Authorization to Implement a Reverse Stock Split For Against Abstain Votes 104,229,120 25,372,666 4,016,453 The vote required to approve Proposal No. 5, discretionary authority for the Company’s Board of Directors (the “ Board ”) to have the option to implement a reverse stock split of the Company’s issued and outstanding shares of common stock, par value $0.001 per share (“ Common Stock ”), at a ratio of between 1-for-2 and 1-for-30 (the “ Reverse Split ”), with the exact ratio to be determined by the Board, and the filing of an amendment to the Company’s Restated and Amended Articles of Incorporation, as amended, with the Nevada Secretary of State to effect the Reverse Split at any time as the Board may deem necessary and advisable prior to October 14, 2023, the one-year anniversary of the initial date of the Company’s 2022 Annual Meeting of Stockholders (the “ Annual Meeting ”) (the “ Reverse Split Authorization ”), was the affirmative vote”
H. Ralph Snodgrass was terminated as President and Chief Scientific Officer at Vistagen Therapeutics, Inc..
“On and effective June 15, 2022, VistaGen Therapeutics, Inc. (the “Company”) terminated the employment of H. Ralph Snodgrass, Ph.D., who served as the Company’s President and Chief Scientific Officer.”
Reid G. Adler was appointed as Chief Legal Officer at Vistagen Therapeutics, Inc..
“On May 2, 2022, the Board of Directors (the “ Board ”) of VistaGen Therapeutics, Inc. (the “ Company ”), appointed Mr. Reid G. Adler, age 67, as the Company’s Chief Legal Officer.”
Margaret M. FitzPatrick was appointed as Director at Vistagen Therapeutics, Inc..
“the Board appointed Margaret M. FitzPatrick to serve on the Board.”
Brian J. Underdown retired as Director at Vistagen Therapeutics, Inc..
“Dr. Brian J. Underdown notified the Board of Directors (the “ Board ”) of VistaGen Therapeutics, Inc. (the “ Company ”) of his retirement from the Board and all Board committees, effective immediately.”
Mary L. Rotunno was appointed as Director at Vistagen Therapeutics, Inc..
“On July 6, 2021, Mary L. Rotunno J.D. was appointed to serve on the Board of Directors”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.